Edition:
United States

Quidel Corp (QDEL.OQ)

QDEL.OQ on NASDAQ Stock Exchange Global Select Market

45.87USD
16 Feb 2018
Change (% chg)

$0.77 (+1.71%)
Prev Close
$45.10
Open
$44.89
Day's High
$46.22
Day's Low
$44.79
Volume
82,740
Avg. Vol
113,600
52-wk High
$49.45
52-wk Low
$20.43

Chart for

About

Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions are separated into four product categories: immunoassays, molecular assays, virology and specialty products. The Company sells its products directly to end users and distributors, in... (more)

Overall

Beta: 0.99
Market Cap(Mil.): $1,559.44
Shares Outstanding(Mil.): 34.00
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 46.02 17.27
EPS (TTM): -- -- --
ROI: -- 9.08 35.43
ROE: -- 13.32 17.10

BRIEF-Quidel Receives 510(K) Clearance For Quickvue Influenza A+B Test

* QUIDEL RECEIVES 510(K) CLEARANCE FOR QUICKVUE INFLUENZA A+B TEST, ASSAY MEETS FDA'S CLASS II RIDT REQUIREMENTS

Feb 13 2018

BRIEF-Quidel Receives FDA Clearance And Clia Waiver For Its Point-Of-Care Sofia® 2 Instrument

* QUIDEL RECEIVES FDA CLEARANCE AND CLIA WAIVER FOR ITS POINT-OF-CARE SOFIA® 2 INSTRUMENT FOR USE WITH SOFIA STREP A+ ASSAY Source text for Eikon: Further company coverage: ( Bangalore.newsroom@thomsonreuters.com )

Dec 21 2017

BRIEF-Quidel Says Confident In Validity Of Supply Agreement With Beckman Coulter To Sell BNP Assay Assets

* QUIDEL CONFIDENT IN LEGAL STRENGTH AND VALIDITY OF SUPPLY AGREEMENT WITH BECKMAN COULTER TO SELL BNP ASSAY ASSETS

Nov 27 2017

BRIEF-Quidel Corp reports Q3 GAAP loss per share $0.16

* Q3 earnings per share view $-0.04 -- Thomson Reuters I/B/E/S

Nov 01 2017

BRIEF-Quidel receives FDA clearance for its point-of-care Sofia® Lyme FIA

* Quidel receives FDA clearance for its point-of-care Sofia® Lyme FIA

Oct 23 2017

BRIEF-Quidel gets FDA nod for Solana Assay molecular diagnostic test

* Quidel receives FDA clearance for its Solana RSV + hMPV Assay

Oct 17 2017

BRIEF-Quidel Corp says ‍on Oct 6, co entered into credit agreement​

* Quidel corp says ‍on Oct 6, co entered into credit agreement​ - sec filing

Oct 06 2017

BRIEF-QUIDEL ANNOUNCES EARLY TERMINATION OF HART-SCOTT-RODINO WAITING PERIOD ON DEAL FOR ALERE'S ASSAY BUSINESS

* QUIDEL ANNOUNCES EARLY TERMINATION OF THE HART-SCOTT-RODINO WAITING PERIOD FOR ITS PENDING ACQUISITION OF ALERE’S TRIAGE® B-TYPE NATURIETIC PEPTIDE (BNP) ASSAY BUSINESS RUN ON BECKMAN COULTER ANALYZERS

Sep 28 2017

BRIEF-Quidel announces revised agreement for pending acquisition of Alere’s business

* Quidel announces revised agreement for its pending acquisition of Alere’s B-type Naturietic Peptide (BNP) assay business run on Beckman Coulter Analyzers

Sep 18 2017

Competitors

Earnings vs. Estimates